MTOR and neoplasm: In addition to DEPTOR, a number of other genes encoding mTOR components were also distinctly amplified in the SUC2/PCF-IDT metastatic prostate cancer dataset (AKT1S1, 2.7%; MLST8, 7.7%; MAPKAP1, 4.5%; RPTOR, 7%; RICTOR, 5%; TELO2, 6.5%; TTI1, 2.5%, Table S3), which could potentially facilitate tumor progression.